A vaccine developed to tackle Streptococcus suis, an economically damaging disease endemic in the global pig population, has ...
Nirsevimab may offer infants stronger protection against severe respiratory syncytial virus than maternal vaccination, ...
Valneva has withdrawn the Biologics License Application for its chikungunya vaccine Ixchiq® following license suspension by the FDA in August 2025.
There has been a rise in cases in districts such as Chennai, Villupuram, Tenkasi, Theni, Cuddalore, Chengalpattu, Kancheepuram and Ariyalur.
Strasbourg, France, January 23, 2026, 8:00 a.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced th ...
Trump made the remarks on Wednesday at the 56th Annual Summit of the World Economic Forum in Davos, Switzerland. His comments came amid talks on global economic issues and shifting geopolitical ...
A planned U.S.-funded study of a hepatitis B vaccine drew widespread condemnation from researchers. Now the host country says it cannot proceed.
The University of Auckland is hosting the research as part of the Global COVID Vaccine Safety (GCoVS) Project. Scientists ...
A new comprehensive review from researchers at the Icahn School of Medicine at Mount Sinai details how decades of cancer ...
The U.S. is giving $1.6 million to researchers to study how the hepatitis B vaccine affects newborns in Guinea-Bissau. Local ...
Inovio Pharmaceuticals faces an October 30 PDUFA date for INO-3107 with high regulatory risk and only a 5-7 month cash runway. Read why INO stock is a hold.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback